Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism

European Journal of Clinical Investigation

Volumn 28, Issue 10, 1998, Pages 807-812

  Hoffer, M J V ^a   Sijbrands, E J G ^a   De Man, F H A F ^a   Havekes, L M ^a,b   Smelt, A H M ^a   Frants, R R ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c MGC Department of Human Genetics   (Netherlands)

Author keywords

Apolipoprotein C3; Combined hyperlipidaemia; DNA polymorphism; Dysbetalipoproteinaemia; Endogenous hypertriglyceridaemia

Indexed keywords

APOLIPOPROTEIN C3; RESTRICTION ENDONUCLEASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILIAL HYPERLIPEMIA; HAPLOTYPE; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; HAPLOTYPES; HUMANS; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK;

EID: 0031768693     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00361.x     Document Type: Article

References (30)

1. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25: 313-20.
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
3. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-90.
4. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992; 33: 995-1003.
5. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249: 790-3.
6. Aalto-Setälä K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (Apo) CIII transgenic mice. J Clin Invest 1992; 90: 1889-900.
7. Shoulders CC, Grantham TT, North JD, et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum Genet 1996; 98: 557-66.
8. Ordovas JM, Civeira F, Genest J Jr, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991; 87: 75-86.
9. Anderson RA, Burns TL, Lee J, Swenson D, Bristow JL. Restriction fragment length polymorphisms associated with abnormal lipid levels in an adolescent population. Atherosclerosis 1989; 77: 227-37.
10. Bredie SJH, van Drongelen J, Kiemeney LA, Demacker PNM, Beaty TH, Stalenhoef AFH. Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17: 834-40.
11. Gehrisch S, Tesche R, Kostka H, Julius U, Jaross W. Point mutations in the hepatic triglyceride lipase (HTGL) gene in familial combined hyperlipidemia. Circulation 1995; 92: 493.
12. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 1995; 95: 371-5.
13. Tybjaerg Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993; 100: 157-69.
14. Hayden MR, Kirk H, Clark C, et al. DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet 1987; 40: 421-30.
15. Henderson HE, Landon SV, Michie J, Berger GM. Association of a DNA polymorphism in the apolipoprotein C-III gene with diverse hyperlipidaemic phenotypes. Hum Genet 1987; 75: 62-5.
16. Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nikkila E. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis 1987; 66: 145-52.
17. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia. Lancet 1983; 1: 444-6.
18. Dallinga-Thie GM, Bu XD, Trip MV, Rotter JI, Lusis AJ, De Bruin TWA. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: Effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37: 136-47.
19. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90: 4562-6.
20. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles. J Lipid Res 1985; 26: 451-6.
21. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-5.
22. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994; 35: 1918-24.
23. Anonymous. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-69.
24. Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987; 28: 455-63.
25. Reymer PWA, Groenemeyer BE, Van de Burg R, Kastelein JJP. Apolipoprotein E genotyping on agarose gels. Clin Chem 1995; 41: 1046-7.
26. Smit M, De Knijff P, Rosseneu M, et al. Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 1988; 80: 287-92.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 1988; 16: 1215.
28. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
29. Marcil M, Boucher B, Gagné E, Davignon J, Hayden M, Genest J Jr. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familiar combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res 1996; 37: 309-19.
30. Van Barlingen, HHJJ, Kock LAW, De Man, FHAF, Erkelens DW, De Bruin TWA. In vitro lipolysis of human VLDL. Effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Atherosclerosis 1996; 121: 75-84.